📍Company: $TENNOR THERAP-B (06872.HK)$
💰Offer Price: 75.7 HKD
📚Number of Shares per Lot: 50 shares
📙Issue Ratio: 16%
🚪Entry Fee: 3,823.17 HKD
♋Green Shoe: Available
🪨Cornerstone Allocation: 37.16%
🏠Post-Issue Market Cap: 3.918 billion HKD
1️⃣Basic Information
Founded in 2013, the company is a biotech firm nearing commercialization, focusing on discovering, developing, and commercializing differentiated innovative drug products to address unmet clinical needs in bacterial infections and bacteria-related metabolic diseases.
As of the latest practicable date, the company has built a differentiated pipeline consisting of seven innovative assets, including two core products:
1. TNP-2198 (Leflitonazole), a novel molecular entity (NME) drug candidate in China and the US as part of a triple therapy combined with amoxicillin and PPI to treat Helicobacter pylori (H. pylori) infections. It is also being developed as a monotherapy in China for treating bacterial vaginosis and Clostridioides difficile infections.
2. TNP-2092 injection, a triple-target treatment for implant-related bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and prosthetic joint infections (PJI), as well as left ventricular assist device infections (LVADI) and central venous catheter-related bloodstream infections (CRBSI) in China and the US...